Suppression of the development of uterine adenomyosis by danazol treatment in mice.
Inhibitory effects of danazol, an isoxazol derivative of synthetic steroid 17 alpha-ethinyl-testosterone, on the development of uterine adenomyosis, a pathological disorder of endometrial tissue defined as the presence of endometrial glands and stroma in the myometrium, were investigated in mice of SHN strain. Mice treated with 0.5 microgram danazol for 5 weeks during 4-9 weeks of age and killed at 21 weeks of age showed significantly lower incidence of the spontaneous development of adenomyosis than the age-matched intact control mice. The inhibitory effects of danazol were also evident in mice bearing pituitary isografts which were effective in inducing an early and a high incidence of adenomyosis. Furthermore, the treatment with danazol resulted in the decrease of serum levels of luteinizing hormone (LH) and prolactin (PRL) associated with hypofunction of ovaries and persistent diestrus. These results support the usefulness of danazol for the clinical treatment of gynecological disorders except for hypofunction of ovaries.
Singtripop
T
T
Zoological Institute, Faculty of Science, University of Tokyo, Japan.
Mori
T
T
Sakamoto
S
S
Sassa
S
S
Park
M K
MK
Kawashima
S
S
D000818:Animals; D003613:Danazol / Q000494:pharmacology*; D004715:Endometriosis / Q000473:pathology / Q000517:prevention & control*; D004971:Estrus / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D051379:Mice; D010053:Ovary / Q000187:drug effects / Q000473:pathology; D010902:Pituitary Gland / Q000637:transplantation; D010903:Pituitary Gland, Anterior; D011388:Prolactin / Q000097:blood; D014599:Uterus / Q000187:drug effects / Q000473:pathology
D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003613:Danazol